Matinas BioPharma Holdings
Stock Forecast, Prediction & Price Target
Matinas BioPharma Holdings Financial Estimates
Matinas BioPharma Holdings Revenue Estimates
Matinas BioPharma Holdings EBITDA Estimates
Matinas BioPharma Holdings Earnings per Share Estimates
| Passed | Analyst forecast | ||||||
|---|---|---|---|---|---|---|---|
| Metric | 12/31/2021 | 12/31/2022 | 12/31/2023 | 12/31/2025 | 12/31/2026 | 12/31/2027 | 12/31/2028 |
Revenue
% change YoY
| $33.33K N/A | $3.18M 9464.09% | $1.09M -65.62% | Avg: $63.91M Low: $63.91M High: $63.91M avg. 5731.84% | Avg: $93.32M Low: $93.32M High: $93.32M avg. 46.00% | Avg: $45.20M Low: $45.20M High: $45.20M avg. -51.56% | Avg: $120.08M Low: $120.08M High: $120.08M avg. 165.67% |
Net Income
% change YoY
| $-21.17M N/A | $-13.01M 38.53% | $-22.94M -76.27% | Avg: $-34.61M Low: $-26.07M High: $-21.72M avg. -50.89% | Avg: $-35.83M Low: $-26.07M High: $-19.55M avg. -3.50% | Avg: $-9.77M Low: $-9.77M High: $-9.77M avg. 72.71% | Avg: $52.14M Low: $52.14M High: $52.14M avg. 633.33% |
EBITDA
% change YoY
| $-26.06M N/A | $-28.08M -7.74% | $-22.82M 18.71% | Avg: $-63.91M Low: $-63.91M High: $-63.91M avg. -180.03% | Avg: $-93.32M Low: $-93.32M High: $-93.32M avg. -46.00% | Avg: $-45.20M Low: $-45.20M High: $-45.20M avg. 51.56% | Avg: $-120.08M Low: $-120.08M High: $-120.08M avg. -165.67% |
EPS
% change YoY
| -$0.1 N/A | -$0.06 40.00% | -$5.28 -8700.00% | Avg: -$0.11 Low: -$0.12 High: -$0.1 avg. 97.91% | Avg: -$0.11 Low: -$0.12 High: -$0.09 avg. 4.54% | Avg: -$0.05 Low: -$0.05 High: -$0.05 avg. 57.14% | Avg: $0.24 Low: $0.24 High: $0.24 avg. 633.33% |
Operating Expenses
% change YoY
| $24.76M N/A | $11.1M -55.18% | $24.86M 123.98% | Avg: $5.97B Low: $5.97B High: $5.97B avg. 23923.79% | Avg: $8.72B Low: $8.72B High: $8.72B avg. 46.00% | Avg: $4.22B Low: $4.22B High: $4.22B avg. -51.56% | Avg: $11.22B Low: $11.22B High: $11.22B avg. 165.67% |
FAQ
What is Matinas BioPharma Holdings stock earnings growth forecast?
Wall Street analysts estimate the annual average earnings growth rate of 162.91% in 2025-2028.
We have gathered data from 2 analysts. Their low estimate is -26.07M, average is -34.61M and high is -21.72M.
What is Matinas BioPharma Holdings stock revenue growth forecast?
Wall Street analysts forecast annual average revenue growth of 1472.98% in 2025-2028.
We have gathered data from 2 analysts. Their low revenue estimate is $63.91M, average is $63.91M and high is $63.91M.
What is Matinas BioPharma Holdings stock earnings per share growth forecast?
Wall Street analysts forecast annual average earnings growth of 198.23% in 2025-2028.
We have gathered data from 2 analysts. Their low earnings per share estimate is -$0.12, average is -$0.11 and high is $-0.1.